Kornimate/medical-research-clean huggingface dataset:
colonoscopy followup after positive fecal occult blood test- understanding barriers to adherence

Conditions: Colorectal Cancer

Summary: approximately 40% of members with a positive fecal occult blood result do not continue to followup colonoscopy in meuhedet. the purpose of this study is to identify the structural, process, carer and patient related causes of undertreatment and suggest appropriate organisational interventions. using both quantitative and qualitative methods, the investigators will identify organisational and personal barriers to completion of followup of positive fobt.

colorectal cancer is the second in incidence and mortality among malignant tumors. early detection of the disease is an effective means of reducing mortality and is possible through a fecal occult blood test. in the case of a positive result colonoscopy is required. in israel, about 30% of people with a positive occult blood test do not perform a follow-up test. the aim of the study is to identify existing barriers to undergoing colonoscopy in a normal-risk population and improving adherence through different intervention mechanisms. at the end of the study we will describe effective intervention models at three levels: the patient, physicians and the organisation to improve early detection of colon cancer. innovation of the study * it will focus on the normal-risk population groups in israel with a positive occult blood that didn't undergo colonoscopy. * will identify the barriers in diverse populations * will review the accessibility of diagnostic facilities forcolon cancer in israel. * will propose intervention programs to improve adherence at all levels in the process. study methods: a prospective study sing both both quantitative and qualitative methods in meuhedet health services target population: health system managers, physicians, and patients (a representative sample of 200 patients adhere colonoscopy and 600 that didn't adhere). data collection databases from meuhedet. the study will include questionnaires, focus groups and interviews. stages of the study: 1. describe the magnitude of the problem 2. map the barriers to adherence with colonoscopy recommendations among patients, physicians and geographic availability of colonoscopies facilities. 3. suggest intervention models for physicians, patients and organisations according to the information provided by data collection. 4. recommendation to decision makers on the implementation of national policy intervention. data processing: will use spss statistical analysis with the types of variables.

Eligibility criteria:
inclusion criteria: members of mhc aged 50-74 who completed a fecal occult blood test during the study period. exclusion criteria: none
diagnostic outcomes of patients presenting with per rectal bleed in surgical departments of services hospital lahore

Conditions: Rectal Bleeding

Summary: it is a cross sectional study in which investigators will be recruiting patients of any sex above 12 years of age who will present to surgical outdoor with per rectal bleed. investigators will then follow them through investigations to reach a certain diagnosis. then investigators will be able to compile the data of diseases and their frequency, which are presenting with rectal bleed in their setup.


Eligibility criteria:
inclusion criteria: * patient of any sex above 12 years old * patients with rectal bleed in opd exclusion criteria: * patient with acute rectal bleeding due to infection like dysentry * acute proctitis * acute colitis
biomarker study in tissue samples from patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. purpose: this research study is studying biomarkers in tissue samples from patients with acute myeloid leukemia.

objectives: * determine the frequency of acute myeloid leukemia (aml) that originates in cd33+ precursors or in which uncontrolled growth is restricted to cd33+ precursors. outline: cryopreserved acute myeloid leukemia cell samples are separated from endothelial cell by fluorescent-activated cell sorting (facs) and analyzed for x-chromosome inactivation patterns by cytogenetic/molecular analysis and/or humara assay.

Eligibility criteria:
disease characteristics: * diagnosed with acute myeloid leukemia * known cd34+ progenitor cells * available freshly isolated, uncultured cell samples patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adult acute myeloid leukemia childhood acute myeloid leukemia/other myeloid malignancies
artificial intelligence-enable electrocardiogram for diagnosis and outcome in hyperthyroidism

Conditions: Hyperthyroidism

Summary: hyperthyroidism


Eligibility criteria:
inclusion criteria: * patients in outpatient department. * patients recieved at least 1 ecg examination. * patients without tsh test before ecg examination or patients with subclinical hyperthyroidism without anti-thyroid drug usage. exclusion criteria: * the patients recieved ecg at the period of inactive ai-ecg system.
repetitive transcranial magnetic stimulation for the treatment of freezing of gait in parkinson's disease

Conditions: Parkinson Disease; Gait Disorders, Neurologic

Summary: freezing of gait (fog) is a common and devastating symptom in advanced stage parkinson's disease (pd), which contributes to falls and disability. unfortunately, there is no effective pharmacological treatment for fog. it is suggested that the cortex-basal ganglia circuit, especially the frontal lobe, plays an important role in the pathogenesis of fog. repetitive transcranial magnetic stimulation (rtms) effects over the cortex and affects the subcortical neural circuits. previous studies have demonstrated that rtms can improve fog for pd patients. in the present randomized controlled trial (rct) study, the invastigators aim to investigate the efficiency of rtms over different motor regions of frontal lobe. the efficacy of treatment is evaluated by the score of fog questionnaire and fog provoking test, and the changing of neural network shown by functional magnetic resonance imaging (fmri). then the effects of rtms over different brain regions will be compared for choosing a better target. the study will provide the evidence for non-invasive neuro-modulation of parkinson's disease with freezing of gait (pd-fog).


Eligibility criteria:
inclusion criteria: * subjects fulfilled the diagnosis of idiopathic parkinson's disease according to mds-pd criteria * hoehn \& yahr (h-y) stage was 2 or 3 * all subjects had freezing of gait which was identified by fogq exclusion criteria: * cognitive impairment (mmse score\ 25) * severe visual and/or haring impairment * significant medical or psychiatric illnesses * history of deep brain stimulation (dbs) surgery or pacemaker implantation. mri cannot be performed in those patients * current treatment with medication cannot be maintained during the study

Keywords: freezing of gait fmri rtms
adaptive immune response to covid-19 vaccination

Conditions: SARS-CoV-2 Vaccination

Summary: aicovi (adaptive immune response to covid-19 vaccination) is a prospective clinical cohort study aiming at studying the kinetics of vaccine-specific antibody production after covid-19 vaccination in health care workers.

aicovi (adaptive immune response to covid-19 vaccination) is a prospective clinical cohort study aiming at elucidating the kinetics of vaccine-specific antibody production after covid-19 vaccination in health care workers at the greifswald university hospital. participants were recruited before their intended vaccination. participants received the basic immunization with either two i. m. doses of bnt162b2 (comirnaty®, tozinameran (inn), biontech/pfizer) with a time interval of 21 days or two i. m. dose of azd 1222 (vaxzevria®, covishield®, chadox1 ncov-19, oxford university/astra-zeneca) with a time interval of 12 weeks (homologous vaccination), or one i. m. dose of azd 1222 as the first vaccination and one i. m. dose of bnt162b2 or mrna-1273 (spikevax®, elasomeran (inn), moderna) as the second vaccination with a time interval of at least 4 weeks (heterologous vaccination). approximately 6 months later, participants received a booster vaccination with bnt162b2. within the study, volunteers donate peripheral blood by venipuncture on each day of vaccination as well as 7 and 14 days after each vaccination. edta plasma and peripheral mononuclear cells (pbmcs) are prepared and stored at -20 °c. volunteers are also asked to complete a standardized questionnaire on each day of blood sampling. questionnaires collect data about physical characteristics, covid-19 vaccination, previous sars-cov-2 infection as well as current infections, medication, immune relevant diseases and side effects of the vaccination.

Eligibility criteria:
inclusion criteria: * planned participation in covid-19 vaccination * completion of the 18th year of life * verbal and written consent given exclusion criteria: * current infectious diseases * underweight (bmi\<18,5) * blood coagulation disorders, anemia or similar diseases * known congenital or acquired immunodeficiencies inclusion criteria for control/validation group of trp participants: * informed written consent

Keywords: vaccine vaccination sars-cov-2 covid-19 immune response immunokinetics
feasibility of wearable biosensors for monitoring daily activity, heart rate, and sleep among patients with decompensated cirrhosis

Conditions: Liver Cirrhosis, Alcoholic

Summary: in this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis. this is a feasibility pilot study that will recruit 20 patients. the investigators plan to determine the feasibility of wearable devices to remotely monitor daily activity (e.g., physical activity, sedentary time, sleep), cognitive function, blood pressure, and weight in patients with decompensated cirrhosis, by assessing patient compliance. a patient is considered compliant if they wear the wristwatch at least 10 hours per day and use the apps, body weight scale, and blood pressure monitor for at least 4 of 7 days


Eligibility criteria:
inclusion criteria: - patients with an admission diagnosis of decompensated cirrhosis based on child-turcotte-pugh score of ≥ 7 or meld-na score ≥ 15, measured prior to discharge from the hospital. cirrhosis of any etiology may be included. however, patients with cirrhosis due to autoimmune hepatitis must be on a stable corticosteroid dose for three months or more before study inclusion. 2.4.2 18 years or older 2.4.3 ambulatory (use of walking aids, such as cane and rollator, is acceptable) 2.4.4 have an understanding, ability, and willingness to fully comply with study procedures and restrictions as determined by the principal investigator. 2.4.5 informed consent obtained from the subject and the ability of the subject to comply with the requirements of the study. exclusion criteria: * 2.5.1 using a pacemaker, implantable cardiac defibrillator, neurostimulator, implantable hearing aids, cochlear implants, or other electronic medical equipment. however, removable hearing aids are permitted. 2.5.2 presence of advanced or terminal stage hepatocellular carcinoma 2.5.3 patients with current extrahepatic malignancies including solid tumors and hematologic disorders 2.5.4 patients with an ongoing aclf (see diagnostic criteria in reference16) 2.5.5 patients with a history of significant extrahepatic disease with impaired short-term prognosis, including congestive heart failure new york heart association grade iii/iv, copd gold \>2, chronic kidney disease defined by kdigo criteria, or under renal replacement therapy. 2.5.6 presence of any extra-hepatic malignancy not in remission for \> 12 months 2.5.7 pregnancy, since being pregnant may alter heart rate and sleep patterns. women of childbearing age remain eligible. 2.5.8 inability or refusal to provide informed consent by the patient 2.5.9 patients with hepatic encephalopathy new haven grade 1 or greater. 2.5.10 any records flagged "break the glass" or "research opt out."
validation of a laboratory test measuring natalizumab (tysabri®) serum levels in ms

Conditions: Multiple Sclerosis

Summary: validating a peptide-based laboratory test enabling the measurement of tysabri® serum levels (pharmacokinetics, pk) in multiple sclerosis patients undergoing therapy. the results of this newly developed test will be compared to tysabri® serum levels measured in parallel using an independent test. we will also simultaneously measure a pharmacodynamic marker of tysabri®, receptor saturation levels on blood immune cells, which is thought to correlate with tysabri® serum levels.

from a single site, consenting patients with relapsing forms of multiple sclerosis who are currently begin treated with tysabri® (natalizumab) and meeting the eligibility criteria will be asked to provide blood samples on the same day, and prior to, a scheduled infusion of tysabri® 300 mg iv. up to 500 patients will be enrolled in this study. each patient may be asked to donate blood up to 2 times (one blood draw per cycle) to obtain longitudinal data points. each patient will also be asked to fill out a wellness patient reported outcome (pro) questionnaire along with the blood draws

Eligibility criteria:
inclusion criteria: * infusing with tysabri at a single site, rocky mountain ms clinic exclusion criteria: * if subject donated or received blood, plasma, or any other blood products between the last tysabri® infusion and the time of sample collection.
study to evaluate the efficacy, safety, and tolerability of valbenazine as an adjunctive treatment for schizophrenia

Conditions: Schizophrenia

Summary: this primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.


Eligibility criteria:
key inclusion criteria: * medically confirmed diagnosis of schizophrenia * participant is receiving a stable regimen of background antipsychotic medication * plasma levels for at least 1 of the participant's antipsychotic medications must be detectable by an available assay * participant is an outpatient with stable symptomatology * participant must have an adult informant (for example, a family member, relative, partner, social worker, caseworker, residential facility staff, or nurse) key exclusion criteria: * has a history of treatment resistant schizophrenia * have a clinically significant unstable medical condition in the judgement of the investigator or any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit * prior (within 6 months of screening) or concomitant use of any vesicular monoamine transporter 2 (vmat2) inhibitor (that is, valbenazine, reserpine, tetrabenazine, deutetrabenazine); or a history of intolerance to vmat2 inhibitors

Keywords: schizophrenia valbenazine antipsychotic vmat2 nbi-98854 dopamine panss adjunctive
icotinib in non-small cell lung cancer patients with uncommon egfr mutation

Conditions: Non-small Cell Lung Cancer

Summary: this study aims to evaluate the efficacy of icotinib, a first generation egfr tki, in non-small cell lung cancer patients harboring uncommon egfr mutation


Eligibility criteria:
inclusion criteria: * patients with stage iiib/iv non-small cell lung cancer * patients with uncommon epidermal growth factor receptor (egfr) mutation * targeted-therapy-naive patients * eastern cooperative oncology group (ecog) performance status 0, 1 or 2 * evaluable target lesions according to recist 1.1 for tumour response assessment exclusion criteria: * wild-type egfr * positive 19 del and/or 21 l858r mutation * previous treatment with egfr tkis such as gefitinib, erlotinib, and afatinib * patients who have documented history of interstitial lung disease
a phase 2 study exploring the safety and efficacy of novel drug treatment in subjects with diabetic macular edema (dme)

Conditions: Diabetes Mellitus; Diabetic Retinopathy

Summary: this study will evaluate the safety and efficacy of ag-014699 in diabetic patients


Eligibility criteria:
inclusion criteria: * diabetic patients, either man or woman, with diabetic retinopathy, at least 18 years of age exclusion criteria: * patients treated with laser therapy within the last 90 days * patients with likelyhood to require cataract surgery within 3 months * uncontrolled diabetes
statins in reducing events in the elderly (staree) heart sub-study

Conditions: Heart Failure; Atrial Fibrillation; Healthy Ageing; Hypercholesterolemia; Myocardial Dysfunction

Summary: the staree-heart sub-study will examine the effect of statin treatment over a 3-year period compared with placebo on markers of cardiac ageing (myocardial dysfunction). this will include determining global longitudinal strain with transthoracic echocardiography, atrial fibrillation with home measures twice daily for two weeks and changes in biomarkers.

staree-heart is an ancillary study nested in the statins in reducing events in the elderly (staree) double-blind randomised placebo-controlled trial. staree is investigating whether statins can prolong good health and maintain independence amongst older people and is enrolling men and women 70 years of age and over who are free from cardiovascular disease, diabetes and dementia. staree-heart will recruit a subset of staree participants before they are randomised to staree study drug. staree-heart will involve an additional suite of cardiac assessments in these participants and will provide detailed information about the clinical effect of statins on myocardial function.

Eligibility criteria:
inclusion criteria: * men and women aged ≥70 years living independently in the community who are participants in the staree rct and eligible for randomisation to study medication. * willing and able to provide informed consent and accept the staree-heart study requirements, including attendance for an echocardiogram and undertaking home monitoring via ecg. exclusion criteria: * known atrial fibrillation or atrial flutter. * participants who do not wish to be informed of an abnormality under any circumstances, regardless of severity, will not be enrolled in the study.

Keywords: statin atorvastatin staree echocardiography atrial fibrillation screening global longitudinal strain single time point screening elderly
study comparing 80 mg of adalimumab with placebo, and demonstrating the non-inferiority of monthly 80 mg adalimumab dosing compared with 40 mg adalimumab every other week dosing

Conditions: Rheumatoid Arthritis

Summary: to demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo and demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab every other week.

the objective of this study is to demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo as measured by acr20 response criteria following 12 weeks of therapy. the study is also designed to demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab eow as measured by acr20 response criteria at week 12.

Eligibility criteria:
inclusion criteria: * subject \> 18 years of age * subject has a diagnosis of ra as defined by the 1987-revised acr-classification criteria and has a disease duration for a minimum of three months * subject must meet the following two criteria: a) at least 6 swollen joints out of 66 assessed, or b) at least 6 tender joints out of 68 assessed * if a subject is on mtx, the doses must be stable for at least 4 weeks prior to screening blood draw and follow standard recommendations for mtx treatment * subject is judged to be in generally good health as determined by the principal investigator exclusion criteria: * subject has previous exposure to any systemic anti-tnf therapy (eg, infliximab, etanercept, certolizumab pegol or golimumab) including adalimumab * subject has a history of acute inflammatory joint disease of different origin other than ra * subject has been treated with any investigational biologic agents * subject considered by the investigator, for any reason, to be an unsuitable candidate for the study * female subject who is pregnant or breast-feeding or considering becoming pregnant
side-specific factors for intraoperative hemodynamic instability in pheochromocytoma

Conditions: adrenalDisease

Summary: the performance of adrenalectomy for pheochromocytoma (pheo) presents significant challenges due to the presence of elevated intraoperative hemodynamic instability (hi) and conversion risk. the objective of this study was to conduct a comparative analysis of the occurrence and determinants of perioperative hypotension (hi) and conversion in left-sided (lla) and right-sided (rla) transabdominal laparoscopic adrenalectomy (tla).

pheochromocytoma (pheo) is a malignancy characterized by the production of catecholamines from chromaffin cells located in the adrenomedullary system. the prevalence of pheo in the general population ranges from 0.05% to 0.1%, however it is more prevalent among those with hypertension. the clinical presentation exhibits a spectrum that spans from asymptomatic to abrupt mortality. minimally invasive laparoscopic adrenalectomy (la) has emerged as a prominent technique in adrenal illness surgery due to its reduced surgical morbidity and death rates, making it the favored method in this field. the initial exploration of transperitoneal laparoscopic adrenalectomy (tla) was conducted by gagner et al. the la procedure encompasses many transabdominal and retroperitoneal techniques, whereas tla is favored by surgeons due to its well-known anatomy and expansive working area. nevertheless, pheo surgery remains a formidable task for surgeons and anesthesiologists due to its established correlation with hemodynamic instability (hi), resulting in symptoms such as abrupt hypertension or tachycardia, as well as severe and protracted hypotension following tumor excision. skilled surgeons and anesthesiologists enhance the outcomes and reduce the occurrence of hypotension. the research has documented a multitude of additional risk factors associated with hi. the observed variability could perhaps be attributed to the lack of consistent anesthesiological and surgical protocols, as well as variations in the definitions of hi. laparoscopic adrenalectomy does not have any absolute contraindications. however, it is worth noting that up to 20% of patients may need to undergo conversion to an open procedure. there has been no specific evaluation of the incidence and risk factors of perioperative hypotension (both intraoperative and postoperative) and conversion rate in a large group of patients undergoing laparoscopic right adrenalectomy (lra) or laparoscopic left adrenalectomy (lla) for managing pheochromocytoma resection.

Eligibility criteria:
inclusion criteria: - patients \>18 years, both sex with unilateral pheo of any size who underwent tla exclusion criteria: * patients who have undergone initial open adrenalectomy, various surgical procedures during total laparoscopic adrenalectomy (tla), complete adrenalectomy, bilateral pheos bleeding diathesis, skeletal deformity, pregnancy, previous homolateral abdominal surgery, missing data, questionable preoperative diagnosis, inherited pheo, or recurrent pheo.